ONCAlert | Upfront Therapy for mRCC
Videos  >  

Updated Findings With Ruxolitinib in Polycythemia Vera

Jean-Jacques Kiladjian, MD, PhD
Published Online:5:25 PM, Fri February 22, 2019

Jean-Jacques Kiladjian, MD, PhD, professor of clinical pharmacology at Paris Diderot University, discusses the 5-year follow-up results from the RESPONSE trial, where more than 65% of patients with polycythemia vera (PV) still remained on treatment with ruxolitinib (Jakafi).

In addition, more than 74% of patients who achieved a primary response maintained this response, Kiladjian says. Of the patients who achieved a complete hematologic response, 54% maintained that response as well.

Kiladjian says he was pleased to see that molecular response was achieved in these patients as the mean JAK2-mutant burden was reduced by 38% after 5 years compared to the baseline. This means the malignant clone can be targeted with ruxolitinib.
Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.